NO20043660L - Salter av valsartan - Google Patents

Salter av valsartan

Info

Publication number: NO20043660L
Authority: NO; Norway
Prior art keywords: valsartan; salts
Prior art date: 2002-02-04

Application number

NO20043660A

Other languages

English (en)

Other versions

NO328155B1 (no

Inventor

Erwin Marti

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-04

Filing date

2004-09-01

Publication date

2004-10-12

2004-09-01 Application filed by Novartis Ag filed Critical Novartis Ag

2004-10-12 Publication of NO20043660L publication Critical patent/NO20043660L/no

2009-12-21 Publication of NO328155B1 publication Critical patent/NO328155B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)

NO20043660A 2002-02-04 2004-09-01 Salt av valsartan NO328155B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US35419902P	2002-02-04	2002-02-04
PCT/EP2003/001047 WO2003066606A1 (en)	2002-02-04	2003-02-03	Salts of valsartan

Publications (2)

Publication Number	Publication Date
NO20043660L true NO20043660L (no)	2004-10-12
NO328155B1 NO328155B1 (no)	2009-12-21

Family

ID=27734333

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20043660A NO328155B1 (no)	2002-02-04	2004-09-01	Salt av valsartan

Country Status (17)

Country	Link
US (3)	US6869970B2 (no)
EP (1)	EP1474402A1 (no)
JP (2)	JP4895475B2 (no)
KR (3)	KR20110101257A (no)
CN (2)	CN100548993C (no)
AU (1)	AU2003214054B2 (no)
BR (1)	BR0307442A (no)
CA (2)	CA2776902A1 (no)
CO (1)	CO5611107A2 (no)
EC (1)	ECSP045221A (no)
MX (1)	MXPA04007525A (no)
NO (1)	NO328155B1 (no)
NZ (1)	NZ534560A (no)
PL (1)	PL370481A1 (no)
RU (1)	RU2004126862A (no)
WO (1)	WO2003066606A1 (no)
ZA (1)	ZA200405698B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7468390B2 (en)	2002-01-17	2008-12-23	Novartis Ag	Methods of treatment and pharmaceutical composition
US6869970B2 (en)	2002-02-04	2005-03-22	Novartis Ag	Crystalline salt forms of valsartan
WO2003105837A1 (en) *	2002-06-13	2003-12-24	Novartis Ag	Calcium salts of indole derived statins
ATE393764T1 (de) *	2003-03-17	2008-05-15	Teva Pharma	Polymorphe formen von valsartan
US20070054947A1 (en) *	2003-05-16	2007-03-08	Cohn Jay N	Pharmaceutical composition comprising valsartan
AU2004289057A1 (en) *	2003-11-14	2005-05-26	Novartis Ag	AT1-receptor antagonists for treating nephrotic syndrome
ITMI20032267A1 (it) *	2003-11-21	2005-05-22	Dinamite Dipharma S P A In Forma A Bbreviata Diph	Procdimento per la preparzione di valsartan e suoi intermedi
WO2005049587A1 (en) *	2003-11-21	2005-06-02	Ranbaxy Laboratories Limited	Process for preparation of biphenyl tetrazole
TWI328006B (en) *	2003-12-26	2010-08-01	Nissan Chemical Ind Ltd	Crystal form of quinoline compound and process for its production
EP1586310B1 (de) *	2004-04-15	2006-12-27	Helm AG	Verfahren zur Herstellung von freifliessenden, pulverförmigen Valsartan-Adsorbaten
PE20060416A1 (es) *	2004-08-03	2006-06-09	Novartis Ag	Composicion de inhibidores de renina e inhibidores de proteinas de efusion
WO2006021443A2 (en) *	2004-08-26	2006-03-02	Novartis Ag	Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
WO2006046528A1 (ja)	2004-10-29	2006-05-04	Kowa Co., Ltd.	糸球体疾患治療剤
US20100028439A1 (en) *	2005-05-23	2010-02-04	Elan Pharma International Limited	Nanoparticulate stabilized anti-hypertensive compositions
AR057882A1 (es) *	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2008035364A2 (en) *	2006-06-23	2008-03-27	Usv Limited	Process for the preparation of micronized valsartan
PE20080991A1 (es)	2006-06-27	2008-09-05	Novartis Ag	Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
WO2008018843A1 (en) *	2006-08-08	2008-02-14	Ulkar Kimya Sanayi Ve Ticaret As	Process for producing useful salts form of biphenyl-tetrazole compounds
PE20080907A1 (es) *	2006-08-31	2008-08-22	Novartis Ag	Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
US8071596B2 (en)	2007-01-12	2011-12-06	Concert Pharmaceuticals, Inc.	Endothelin receptor antagonists
US8080549B2 (en) *	2007-01-12	2011-12-20	Concert Pharmaceuticals, Inc.	Endothelin receptor antagonists
CN101396366B (zh) *	2007-09-25	2010-10-13	浙江华海药业股份有限公司	含缬沙坦的固体口服制剂及其制备方法
ES2336755B1 (es) *	2008-10-07	2011-01-21	Activery Biotech, S.L.	Procedimiento para la preparacion de combinaciones de valsartan y simvastatina.
JP2011063518A (ja) *	2009-09-15	2011-03-31	Tohoku Univ	Ａｒｂ及び／又はグリタゾン系血糖降下物質を含有するｏａｔｐ−ｒ遺伝子発現増強組成物
WO2012016969A1 (en)	2010-08-03	2012-02-09	Novartis Ag	Highly crystalline valsartan
CN103012301B (zh) *	2013-01-05	2015-06-17	江苏施美康药业股份有限公司	缬沙坦甲酯碱金属盐及其制备方法
DE102014004512A1 (de) *	2014-03-28	2015-10-01	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin	Anorganisch-organische Hybridverbindung
WO2017012600A1 (en)	2015-07-20	2017-01-26	Zentiva, K.S.	A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
EP3498698A1 (en)	2017-12-15	2019-06-19	Mankind Pharma Ltd	Solid forms of valsartan disodium and process of preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE59107440D1 (de) *	1990-02-19	1996-04-04	Ciba Geigy Ag	Acylverbindungen
SK133897A3 (en) *	1995-04-07	1998-02-04	Ciba Geigy Ag	Combination compositions containing benazepril or benazeprilat and valsartan
ES2099031B1 (es)	1995-05-31	1997-12-01	Esteve Labor Dr	Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
US5877193A (en) *	1996-07-19	1999-03-02	Hoffmann-La Roche Inc.	Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
CA2282307A1 (en) *	1997-02-28	1998-09-03	Jorma Virtanen	Laboratory in a disk
US6641886B1 (en) *	1999-03-23	2003-11-04	Flexplay Technologies, Inc.	Directory read inhibitor for optical storage media
JP2001155346A (ja) *	1999-11-26	2001-06-08	Toshiba Corp	情報記録媒体、情報記録装置、情報記録方法、情報再生装置、情報再生方法
ES2277301T3 (es)	2000-04-24	2007-07-01	Teva Pharmaceutical Industries Ltd.	Solvato de hemitartrato de zolpidem.
US20020132839A1 (en) *	2000-06-22	2002-09-19	Ganter Sabina Maria	Tablet formulations comprising valsartan
DE60135560D1 (de)	2000-07-19	2008-10-09	Novartis Ag	Valsartan salze
US6869970B2 (en)	2002-02-04	2005-03-22	Novartis Ag	Crystalline salt forms of valsartan

2003
- 2003-01-29 US US10/353,389 patent/US6869970B2/en not_active Expired - Lifetime
- 2003-02-03 PL PL03370481A patent/PL370481A1/xx not_active Application Discontinuation
- 2003-02-03 MX MXPA04007525A patent/MXPA04007525A/es active IP Right Grant
- 2003-02-03 CN CNB038032600A patent/CN100548993C/zh not_active Expired - Lifetime
- 2003-02-03 AU AU2003214054A patent/AU2003214054B2/en not_active Ceased
- 2003-02-03 KR KR1020117020401A patent/KR20110101257A/ko not_active Ceased
- 2003-02-03 KR KR10-2004-7012006A patent/KR20040081178A/ko not_active Ceased
- 2003-02-03 CN CN200910167071XA patent/CN101633646B/zh not_active Expired - Lifetime
- 2003-02-03 JP JP2003565980A patent/JP4895475B2/ja not_active Expired - Fee Related
- 2003-02-03 EP EP03709700A patent/EP1474402A1/en not_active Withdrawn
- 2003-02-03 BR BR0307442-0A patent/BR0307442A/pt active Search and Examination
- 2003-02-03 KR KR1020127011954A patent/KR20120054667A/ko not_active Ceased
- 2003-02-03 NZ NZ534560A patent/NZ534560A/en not_active IP Right Cessation
- 2003-02-03 WO PCT/EP2003/001047 patent/WO2003066606A1/en not_active Ceased
- 2003-02-03 CA CA2776902A patent/CA2776902A1/en not_active Abandoned
- 2003-02-03 RU RU2004126862/04A patent/RU2004126862A/ru unknown
- 2003-02-03 CA CA2474424A patent/CA2474424C/en not_active Expired - Fee Related
2004
- 2004-07-16 ZA ZA200405698A patent/ZA200405698B/en unknown
- 2004-08-04 EC EC2004005221A patent/ECSP045221A/es unknown
- 2004-09-01 NO NO20043660A patent/NO328155B1/no not_active IP Right Cessation
- 2004-09-02 CO CO04086386A patent/CO5611107A2/es not_active Application Discontinuation
- 2004-12-15 US US11/013,111 patent/US8058301B2/en active Active
2009
- 2009-06-10 JP JP2009139245A patent/JP5303370B2/ja not_active Expired - Fee Related
2011
- 2011-09-28 US US13/247,281 patent/US8329919B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2003066606A1 (en)	2003-08-14
AU2003214054A1 (en)	2003-09-02
EP1474402A1 (en)	2004-11-10
KR20040081178A (ko)	2004-09-20
BR0307442A (pt)	2005-01-04
NO328155B1 (no)	2009-12-21
US20050101652A1 (en)	2005-05-12
CA2474424A1 (en)	2003-08-14
US8058301B2 (en)	2011-11-15
CN101633646B (zh)	2012-08-29
US6869970B2 (en)	2005-03-22
KR20120054667A (ko)	2012-05-30
HK1139681A1 (en)	2010-09-24
JP2009235086A (ja)	2009-10-15
MXPA04007525A (es)	2004-11-10
PL370481A1 (en)	2005-05-30
KR20110101257A (ko)	2011-09-15
CN100548993C (zh)	2009-10-14
CA2776902A1 (en)	2003-08-14
JP5303370B2 (ja)	2013-10-02
JP4895475B2 (ja)	2012-03-14
CN1628106A (zh)	2005-06-15
ZA200405698B (en)	2006-05-31
AU2003214054B2 (en)	2007-08-16
CN101633646A (zh)	2010-01-27
CA2474424C (en)	2013-03-26
RU2004126862A (ru)	2005-06-27
US8329919B2 (en)	2012-12-11
ECSP045221A (es)	2004-09-28
US20120022268A1 (en)	2012-01-26
US20030171414A1 (en)	2003-09-11
NZ534560A (en)	2007-05-31
CO5611107A2 (es)	2006-02-28
JP2005517696A (ja)	2005-06-16

Publication	Publication Date	Title
NO20043660L (no)	2004-10-12	Salter av valsartan
CY2015015I1 (el)	2020-05-29	Παραγωγη τιακουμυκινης
ATE478870T1 (de)	2010-09-15	Spiroindolinpiperidinderivate
DK1556385T3 (da)	2010-06-14	Heterocyclocarboxamid-derivater
ATE450506T1 (de)	2009-12-15	Indol-3-schwefelderivate
ATE467631T1 (de)	2010-05-15	Chinuclidinamidderivate
ATE438644T1 (de)	2009-08-15	Chinazolinderivate
IS7720A (is)	2005-03-01	Píperidín-N-oxíð-afleiður
DK1474408T3 (da)	2012-06-25	N-Phenyl-2-pyrimidinaminderivater
DE60333537D1 (de)	2010-09-09	Herzschrittmacher
DK1549242T3 (da)	2013-10-28	Implanterbar sensor
ATE369365T1 (de)	2007-08-15	Kristallines mikronisat des tiotropiumbromids
NO20050118D0 (no)	2005-01-10	Substituerte fenylsulfonamidinhibitorer av beta-amyolid produksjon
DK1478851T3 (da)	2006-11-13	Offshore-vindmöllepark
AU2003214112A1 (en)	2003-09-22	Salts of nateglinide
DE60307512D1 (de)	2006-09-21	3h-chinazoline -4-on derivaten
NO20033408D0 (no)	2003-07-30	Fremgangsmåte for fremstilling av krystallinske nanopartikler
NO20040269L (no)	2004-03-22	Telemetrisystem
ATE423771T1 (de)	2009-03-15	Tetrahydrochinolinderivate
PL394821A1 (pl)	2011-09-12	Sposób wytwarzania kombrestatyn
NO20055485D0 (no)	2005-11-21	Vannloselige salter av risperidon
NO20044867L (no)	2004-12-23	Nye salter
NO20040497L (no)	2004-04-14	Amidinderivater for behandling av amyloidose
DE50306277D1 (de)	2007-02-22	4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
NO20050183L (no)	2005-01-12	Farmasoytiske salter av reboxetin

Legal Events

Date	Code	Title	Description
2014-09-22	MM1K	Lapsed by not paying the annual fees